ENDRA Life Sciences (NDRA) Cash & Equivalents (2016 - 2026)

ENDRA Life Sciences (NDRA) has reported Cash & Equivalents for 11 consecutive years, with $356462.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 82.74% year-over-year to $356462.0; the TTM figure through Mar 2026 stood at $356462.0 (down 82.74% YoY), while the FY2025 annual figure was $762365.0, down 76.39% from the prior year.
• Cash & Equivalents fell to $356462.0 in Q1 2026 per NDRA's latest filing, from $762365.0 in the prior quarter.
• Across five years, Cash & Equivalents topped out at $11.3 million in Q2 2022 and bottomed at $356462.0 in Q1 2026.
• Historically, Cash & Equivalents has averaged $3.9 million across 5 years, with a median of $3.2 million in 2024.
• On a YoY basis, Cash & Equivalents climbed as much as 81.98% in 2025 and fell as far as 83.27% in 2025.
• ENDRA Life Sciences' Cash & Equivalents stood at $4.9 million in 2022, then slumped by 42.04% to $2.8 million in 2023, then increased by 13.96% to $3.2 million in 2024, then tumbled by 76.39% to $762365.0 in 2025, then slumped by 53.24% to $356462.0 in 2026.
• Business Quant data shows NDRA's Cash & Equivalents at $356462.0 in Q1 2026, $762365.0 in Q4 2025, and $794036.0 in Q3 2025.